Citigroup Reaffirms Neutral Rating for GSK (NYSE:GSK)

GSK (NYSE:GSK)‘s stock had its “neutral” rating restated by analysts at Citigroup in a research report issued on Friday, Marketbeat reports.

A number of other equities analysts have also commented on the stock. Royal Bank Of Canada reiterated an “outperform” rating on shares of GSK in a report on Tuesday, June 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of GSK in a research report on Thursday, July 9th. Wall Street Zen raised GSK from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. HSBC upgraded GSK from a “reduce” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Jefferies Financial Group raised GSK to a “strong-buy” rating in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $53.00.

GSK Trading Up 1.3%

Shares of NYSE GSK opened at $51.38 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.52 and a current ratio of 0.79. GSK has a 52-week low of $36.75 and a 52-week high of $61.69. The firm has a 50 day moving average price of $51.58 and a two-hundred day moving average price of $53.39. The stock has a market cap of $103.92 billion, a P/E ratio of 13.35, a price-to-earnings-growth ratio of 3.27 and a beta of 0.35.

Institutional Investors Weigh In On GSK

Several large investors have recently modified their holdings of the company. First Horizon Corp raised its stake in GSK by 78.7% during the fourth quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 236 shares during the last quarter. Elyxium Wealth LLC bought a new stake in GSK during the fourth quarter valued at $30,000. Triumph Capital Management acquired a new stake in GSK during the 3rd quarter worth about $40,000. Coston McIsaac & Partners grew its holdings in GSK by 17.3% during the 4th quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock worth $68,000 after acquiring an additional 206 shares during the period. Finally, Bogart Wealth LLC raised its position in shares of GSK by 15.3% in the 1st quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock worth $83,000 after acquiring an additional 200 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: The FDA approved Jideytro for previously treated ROS1-positive non-small cell lung cancer, marking GSK’s first lung cancer approval and a new catalyst for its oncology pipeline. Article
• Positive Sentiment: Analysts and market commentary highlighted Jideytro’s approval as potentially undervalued, suggesting investors may be underestimating the earnings contribution from GSK’s precision oncology assets. Article
• Positive Sentiment: GSK also received approval in Canada for a prefilled syringe presentation of Shingrix, which should support vaccine convenience and commercial execution. Article
• Neutral Sentiment: Citigroup reaffirmed its neutral rating on GSK, indicating the approval news is positive but not enough to change the bank’s stance yet. Article

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.